MedTrace Logo

BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer

NCT03627390 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-11-15

No results posted yet for this study

Summary

The aim of this study is to investigate the short-term effect and tolerability BP-C1 in patients with metastatic pancreatic cancer who has undergone guideline-recommended chemotherapy.

Conditions

Interventions

DRUG

BP-C1

BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days

DRUG

BP-C2

BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days

Sponsors & Collaborators

  • Meddoc

    collaborator OTHER

  • Norwegian University of Life Sciences

    collaborator OTHER

  • Meabco A/S

    lead INDUSTRY

Principal Investigators

  • Tarek Ibrahim, MD · Department of HPH Surgery, National Liver Institute, University of Menoufia, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-19
Primary Completion
2016-03-04
Completion
2016-03-04

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03627390 on ClinicalTrials.gov